Fezolinetant, sold under the brand name Veozah, was approved by the FDA on May 12, 2023, specifically for use in menopausal adult women to manage symptoms associated with hot flashes and night sweats.
Fezolinetant is an oral medication classified under miscellaneous central nervous system agents. It is designed to alleviate vasomotor symptoms by regulating the body's temperature control mechanisms affected during menopause.
Common side effects of fezolinetant may include:
Serious side effects that require immediate medical attention include:
Before taking fezolinetant, inform your doctor if you have:
Additionally, some drugs should not be used with fezolinetant, including cimetidine, fluvoxamine, and mexiletine. Always inform your doctor about all other medicines you are taking to avoid potential interactions.
If you miss a dose, take it as soon as you remember. However, if you are more than 12 hours late, skip the missed dose and resume your regular schedule. Do not take two doses at once.
Fezolinetant (Veozah) is an FDA-approved medication for managing moderate to severe vasomotor symptoms due to menopause. It is effective in reducing symptoms like hot flashes and night sweats, making it a valuable option for menopausal women seeking relief from these common symptoms. Always consult with your healthcare provider to ensure safe and effective use of this medication.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!